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iterranean spotted fever (MSF), however, is milder than that 
of RMSF, especially in children, and the fatality rate is con- 
sidered to be ^0Zo [2]. In 1993, Wolach and I [3] reported fatal 
MSF in 3 Israeli children who had presented with a febrile 
disease lasting 5-7 days, septic shock, mental changes, hypon- 
atremia, and bleeding tendency. A rash, macular or purpuric, 
was present in 2 children and absent in the third. A presumptive 
diagnosis of meningococcemia or sepsis of unknown origin was 
entertained. The 3 children were empirically treated with 0- 
lactam antibiotics and aggressive supportive therapy but died 
within 24 h of admission. The diagnosis of MSF was confirmed 
in 2 patients by cell culture and by animal inoculation in the 
third. Antibodies to spotted fever-group rickettsiae, as deter- 
mined by microimmunofluorescence, were negative in 2 chil- 
dren, whereas a borderline titer of 1 : 80 was found in 1. 
Early administration of specific therapy with tetracyclines or 
chloramphenicol significantly decreases mortality due to rick- 
ettsial infections [4]. Institution of such therapy, however, re- 
quires that the rickettsial etiology of the illness be suspected 
on clinical and/or epidemiologic grounds, because these anti- 
microbial drugs are not usually given empirically to febrile pa- 
tients. In addition, pediatricians frequently hesitate to start 
therapy with tetracycline in febrile young children without a 
definitive proof of a rickettsial diagnosis, because of the po- 
tential risk of teeth staining. Usually the diagnosis of rickett- 
sioses relies on serologic tests, whereas culture of the organism 
and polymerase chain reaction methods are not routinely used 
or universally available. The series of patients reported by Pad- 
dock et al. [1] and our 3 patients clearly show that serologic 
tests may be unreliable for diagnosing or excluding rickettsial 
infections, especially in persons presenting with fulminant dis- 
ease. Had specific isolation techniques for rickettsiae not been 
attempted, the diagnosis would have been missed in our 3 pa- 
tients, and their deaths would have been attributed to infections 
caused by unidentified pathogens. Thus, it appears that, when 
alternative methods for confirming the disease are not used, 
the diagnosis of MSF may be missed by serology, resulting in 
underestimation of the true case/fatality rate of the infection. 
Because MSF may follow an unpredictable, rapid fatal course 
similar to that of RMSF, it seems prudent to advise prompt 
administration of empirical tetracycline therapy whenever the 
diagnosis is suspected. 
Mortality in Serologically Unconfirmed 
Mediterranean Spotted Fever 
Pablo Yagupsky 
Clinical Microbiology Laboratory, Soroka Medical Center, 
Ben-Gurion University of the Negev, Beer-Sheva, Israel 
To the Editor?I read with interest the article by Paddock et 
al. [1], who described the detection of occult mortality due to 
Rocky Mountain spotted fever (RMSF) by demonstrating 
Rickettsia rickettsii antigens or DNA in blood and tissues [1]. 
In Mediterranean countries, including Israel, spotted fever is 
caused by members of the R. conorii complex, which are an- 
tigenically related to R. rickettsii. The clinical course of Med- 
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Reply 
To the Editor?We appreciate the comments by Yagupsky [1], 
which underscore several of the salient features of spotted fe- 
ver-group rickettsial infections that we emphasized in our re- 
port [2]. For patients, diagnosticians, and clinicians faced with 
the potentially tragic consequences of Rocky Mountain spotted 
fever or severe Mediterranean spotted fever (MSF), these points 
merit repeating. First, the nonspecific signs and symptoms early 
in the course of rickettsial infections mimic many other infec- 
tious and noninfectious syndromes. Second, the diagnostic chal- 
lenges posed by these diseases are compounded by the lack of 
rapid and widely available confirmatory tests early in the course 
of the illnesses. Finally, spotted fevers have the potential to kill 
otherwise healthy persons in ^ week after onset of symptoms, 
emphasizing the need for early administration of appropriate 
therapy. 
The immunohistochemical (IHC) test described in our report 
uses an antibody that reacts with multiple spotted fever-group 
rickettsiae, including members of the Rickettsia conorii complex 
that causes MSF. In this context, we have used this assay to 
diagnose previously unexplained fatal illnesses caused by spot- 
ted fever-group rickettsiae other than R. rickettsii. Our expe- 
rience reinforces the comments of Yagupsky [1] and includes 
confirmation of fatal spotted fever infections in 2 adult Israeli 
patients for whom serologic evidence of MSF was lacking. The 
first patient was a 31-year-old woman who died 6 days after 
onset of an illness characterized by fever, myalgias, headache, 
and respiratory insufficiency. The second patient was a 38-year- 
old man who died 7 days after being hospitalized for fever and 
vomiting. Both patients developed thrombocytopenia and pe- 
techial or purpuric rashes over the course of their illnesses. 
Similar to 2 of the pediatric patients described in the earlier 
report by Yagupsky and Wolach [3], neither of these 2 patients 
demonstrated diagnostic levels of antibody reactive with spot- 
ted fever-group rickettsiae when serum samples were tested by 
use of an indirect immunofluorescence assay. However, tissues 
from both patients obtained at autopsy demonstrated micro- 
scopic lesions consistent with histopathologic findings of fatal 
MSF [4], and IHC staining for spotted fever-group rickettsiae 
revealed abundant rickettsial antigens and intact rickettsiae in 
and around blood vessels and within reticuloendothelial cells 
(figure 1). 
We agree with Yagupsky's recommendation to administer 
tetracycline antimicrobials (preferably doxycycline) to children 
of any age when spotted fever-group rickettsioses are consid- 
ered in the differential diagnosis. The recognized propensity of 
tetracyclines to bind to dental enamel should not dissuade phy- 
sicians from using the most effective drug for the treatment of 
these potentially life-threatening infections. The decision to use 
doxycycline in young children is never made casually, and the 
rationale for this choice of therapy should be discussed with 
the child's parents [5]. However, it should be recognized that a 
single short course (i.e., 5-7 days) of doxycycline should not 
result in cosmetically significant staining of teeth [6, 7]. For 
patients with Rocky Mountain spotted fever or severe MSF, 
there is a relatively narrow window of time during which ef- 
fective antibiotic therapy dramatically reduces the risk of death 
[8]. Since laboratory tests available to most physicians do not 
assist in early diagnosis, initiation of therapy should be based 
on clinical, and especially epidemiologic, findings (e.g., unex- 
plained febrile illness associated with known tick bite or tick 
exposure or unexplained fever with thrombocytopenia, rash, or 
headache occurring during spring or summer months in an area 
where the disease is endemic). 
Isolation of R. conorii from patients' blood and tissues con- 
firmed the diagnosis of spotted fever for each of the 3 pediatric 
patients described by Yagupsky and Wolach [3] and reflects the 
clinical acumen of these investigators. Although isolation is the 
reference standard for diagnosis, culture is seldom attempted 
during the acute phase of illness, even when a rickettsial in- 
fection is suspected, and cannot be performed retrospectively 
on autopsy specimens unless samples were appropriately col- 
lected and stored (e.g., frozen at -70oC). Biosafety level 3 prac- 
tices and facilities are recommended if culture of spotted fe- 
ver-group rickettsiae is attempted [9]. In contrast, IHC testing 
provides a method for retrospective confirmatory diagnosis on 
archived samples months or even years after the illness. In this 
context, IHC is a versatile technique that can help resolve prob- 
lematic issues relating to the diagnosis of otherwise unexplained 
illnesses and provide new insights into the clinical course and 
epidemiologic features of these diseases [10]. 
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Figure 1. Immunohistochemical localization of spotted fever-group rickettsial antigens in tissues of patients with fatal spotted fever, by 
immunoalkaline phosphatase stain with naphthol phosphate-fast red substrate and hematoxylin counterstain. A, Rickettsiae and rickettsial antigens 
associated with damaged endothelium in myocardial interstitium (patient 1); original magnification, X158. B, Abundant rickettsial antigens within 
denuded intravascular endothelial cells in small vessel in kidney (patient 1); original magnification, XlOO. C, Rickettsial nodule in cerebral cortex 
(patient 1); original magnification, X158. D, Spotted fever-group rickettsiae and rickettsial antigens in cytoplasms of Kupffer cells in liver (patient 
2); original magnification, X158. 
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Oropharyngeal Candida Colonization and Human 
Immunodeficiency Virus Type 1 Infection 
To the Editor?Gottfredsson et al. [1], in a cross-sectional study 
of oropharyngeal Candida colonization in 83 patients with hu- 
man immunodeficiency virus type 1 (HIV-1) infection, reported 
that only plasma HIV-1 load was predictive of Candida load; 
neither CD4 lymphocyte level nor use of antiretroviral therapy 
was associated with colonization [1]. They hypothesized that 
high levels of HIV-1 may suppress local mucosal immune re- 
sponses, thereby permitting increased Candida colonization, 
and speculated that control of HIV-1 replication may restore 
local immune function. Their findings certainly are consistent 
with these possibilities. However, there are at least 2 alternative 
explanations that might account for the interesting findings. 
Cross-sectional studies do not provide information about 
causality for any associations found. However, even if high 
levels of HIV-1 do cause increased Candida colonization, sup- 
pressed local mucosal immunity is not the only possible mech- 
anism that might explain such an occurrence. It was recently 
shown in vitro that HIV-1 glycoproteins may promote the vir- 
ulence of Candida albicans [2]. Thus, increased local HIV-1 
replication might have a direct effect on increased Candida colo- 
nization, without necessarily requiring the presence of defects 
in local immune function. Furthermore, such a mechanism need 
not imply disassociation of HIV-1 effects on local mucosal im- 
munity from those on CD4 lymphocyte counts, as would be 
suggested by a better correlation of Candida colonization with 
HIV-1 effects on local immune function than with effects on 
CD4 lymphocyte counts. 
In addition, patient self-report is known to overestimate ad- 
herence to prescribed medications [3], especially for regimens 
requiring multiple doses daily [4]. Preliminary observations of 
HIV-infected current and former drug users in the Bronx, New 
York, showed that medication adherence assessed by electronic 
monitoring was significantly correlated with HIV load but that 
self-reported adherence was not [5]. HIV-1 load is inversely 
correlated with actual use of effective highly active protease 
inhibitor-containing antiretro viral regimens. Even though oro- 
pharyngeal Candida colonization was not independently as- 
sociated with the reported use of protease inhibitors, its asso- 
ciation with HIV-1 load suggests that there may well have been 
less use of protease inhibitors in colonized patients. Since pro- 
tease inhibitors have anticandidal activity [6], it is possible that 
the actual use of protease inhibitors, better reflected by low 
HIV-1 load than by self-reported adherence, had a direct effect 
on reducing oropharyngeal Candida colonization. It would be 
of interest to know if the independent association of Candida 
colonization with HIV-1 load was seen in the subgroup of pa- 
tients known not to have received either current or recent pro- 
tease inhibitor therapy. 
Until longitudinal studies are available and actual rather than 
reported use of chemotherapeutic agents with antifungal activ- 
ity can be accurately measured and controlled for in analyses, 
it may be premature to conclude that HIV-1 load has a direct 
effect on local mucosal immunity, which promotes orophar- 
yngeal Candida colonization. 
Robert S. Klein,1 Julia H. Arnsten,1 and Jack D. Sobel2 
1Departments of Medicine and of Epidemiology and Social Medicine, 
Montefiore Medical Center and Albert Einstein College of Medicine, 
Bronx, New York; 2Department of Medicine, Wayne State University 
School of Medicine, Detroit, Michigan 
References 
1. Gottfredsson M, Cox GM, Indridason OS, de Almeida GMD, Heald AE, 
Perfect JR. Association of plasma levels of human immunodeficiency virus 
type 1 RNA and oropharyngeal Candida colonization. J Infect Dis 1999; 
180:534-7. 
2. Gruber A, Lukasser-Vogl E, Borg-von Zepelin M, Dierich MP, Wiirzner R. 
Human immunodeficiency virus type 1 gpl60 and gp41 binding to Candida 
albicans selectively enhances candidal virulence in vitro. J Infect Dis 
1998;177:1057-63. 
3. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomized 
trials of interventions to assist patients to follow prescriptions for medi- 
cations. Lancet 1996;348:383-6. 
4. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Prybeck TR. The effect 
of prescribed daily dose frequency on patient medication compliance. Arch 
Intern Med 1990; 150:1881^1. 
5. Arnsten JH, Grant RW, Demas PA, Gourevitch MN, Schoenbaum EE. Ad- 
herence with antiretroviral therapy in HIV-infected drug users. J Gen Intern 
Med 1999; 14(Suppl 2):7. 
6. Cassone A, De Bernardis F, Torosantucci A, Tacconelli E, Tumbarello M, 
Cauda R. In vitro and in vivo anticandidal activity of human immuno- 
deficiency virus protease inhibitors. J Infect Dis 1999; 180:448-53. 
Reprints or correspondence: Dr. Robert S. Klein, AIDS Research/Division of 
Infectious Diseases, Montefiore Medical Center, 111 E. 210th St., Bronx, NY 
10476-2490 (klein@aecom.yu.edu). 
The Journal of Infectious Diseases 2000; 181:812 
? 2000 by the Infectious Diseases Society of America. All rights reserved. 
0022-1899/2000/18102-0074502.00 
Reply 
To the Editor?We thank Klein et al. [1] for their cogent re- 
sponse to our work [2] in which we reported that, among var- 
ious clinical parameters in a cohort of human immunodefi- 
ciency virus (HlV)-infected patients, plasma HIV RNA levels 
had the most significant association with oropharyngeal Can- 
dida colonization. As Klein et al. point out, this association 
could be the result of 3 possibilities: HIV affecting mucosal 
